BackG&E Herbal Biotechnology , Ltd. Overview

G&E Herbal Biotechnology , Ltd. Accounts Payable

Track G&E Herbal Biotechnology , Ltd.'s accounts payable ($840K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$836000.00
↑ 18.58% YoYΔ $131000.00 vs prior year quarter

Peer trimmed avg / median

Loading

G&E Herbal Biotechnology , Ltd. Accounts Payable History

Loading

G&E Herbal Biotechnology , Ltd. vs. peers: Accounts Payable Comparison

Loading

G&E Herbal Biotechnology , Ltd. Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

G&E Herbal Biotechnology , Ltd. (4911.TWO) FAQ

G&E Herbal Biotechnology , Ltd.'s accounts payable stands at $840K as of September 2026. That compares with $710K in the prior-year period — up 18.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

G&E Herbal Biotechnology , Ltd. reported $840K in accounts payable versus $710K a year earlier — a 18.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $710K in the prior-year period — up 18.6% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how G&E Herbal Biotechnology , Ltd.'s accounts payable evolved across reporting periods, while the comparison chart places 4911.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. G&E Herbal Biotechnology , Ltd.'s reading of $840K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.